| Recruiting | VE303 for Prevention of Recurrent Clostridioides Difficile Infection NCT06237452 | Vedanta Biosciences, Inc. | Phase 3 |
| Recruiting | FMT in Patients With Recurrent CDI and Ulcerative Colitis: Single Infusion Versus Sequential Approach NCT06071312 | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | Phase 1 / Phase 2 |
| Completed | Animal-Assisted Visitation Program Chlorhexidine Trial NCT04171817 | Johns Hopkins Bloomberg School of Public Health | Phase 4 |
| Active Not Recruiting | REMBRANDT: REcovery of the MicroBiome fRom Antibiotics for Dental implanTs NCT05622721 | University of Pennsylvania | — |
| Completed | Effect of Expanding (Gloving) Barrier Precautions for Reducing Clostridium Difficile Acquisition (and Infectio NCT04036058 | VA Office of Research and Development | N/A |
| Recruiting | Dynamics of Colonization and Infection by Multidrug-Resistant Pathogens in Immunocompromised and Critically Il NCT06258551 | The Methodist Hospital Research Institute | — |
| Withdrawn | Fecal Microbiota Transplantation for Primary Clostridium Difficile Diarrhea NCT02801656 | Memorial University of Newfoundland | Phase 3 |
| Withdrawn | A Non-Interventional Pilot Study to Explore the Role of Gut Flora in Clostridoides Difficile Infection NCT04100603 | ProgenaBiome | — |
| Withdrawn | Randomized Clinical Trial of Standard FMT Treatments NCT04729790 | The University of Texas Health Science Center, Houston | Phase 2 |
| Terminated | Bezlotoxumab as Secondary Prophylaxis for C. Difficile in High-risk Hospitalized Patients Exposed to Antibioti NCT03937999 | Montefiore Medical Center | Phase 4 |
| Completed | Oligosaccharide for Cdiff(+) Heme-onc Patients NCT03778606 | Medical College of Wisconsin | N/A |
| Completed | FQ Restriction for the Prevention of CDI NCT03848689 | University of Wisconsin, Madison | — |
| Completed | Phase 2 Study of VE303 for Prevention of Recurrent Clostridioides Difficile Infection NCT03788434 | Vedanta Biosciences, Inc. | Phase 2 |
| Terminated | Fecal Microbiota Transplant (FMT) Plus Fidaxomicin for Severe or Fulminant Clostridium Difficile Infection NCT03760484 | University of Alberta | Phase 2 |
| Completed | C Difficile Near-patient Diagnostics NCT03857464 | University of Calgary | N/A |
| Terminated | PROCLAIM -- Misoprostol in the Prevention of Recurrent CDI Prevent Recurrence of Clostridium Difficile Infecti NCT03617172 | Vanderbilt University Medical Center | Phase 2 |
| Unknown | Relationship Between C. Difficile Toxins' Serum Level With C. Difficile Infection NCT03586206 | Roma Tre University | — |
| Unknown | Clostridium Difficile Virulence Mechanism Study (CDVM Study) NCT03654872 | Chinese University of Hong Kong | — |
| Unknown | Digestive Microbiota Transplant NCT03606031 | Assistance Publique Hopitaux De Marseille | — |
| Unknown | Prevention of Clostridium Difficile Infections Using Lactobacillus Plantarum 299v Strain NCT03368105 | Medical University of Silesia | N/A |
| Completed | Effectiveness of Isolating Clostridium Difficile Asymptomatic Carriers on the Incidence of Infections NCT03223415 | Yves Longtin | N/A |
| Unknown | Rectal Bacteriotherapy, Fecal Microbiota Transplantation or Oral Vancomycin Treatment of Recurrent Clostridium NCT02774382 | Hvidovre University Hospital | Phase 3 |
| Unknown | Immune Response to C.Difficile Infection NCT02797288 | University of Virginia | — |
| Completed | Antimicrobial Stewardship Program for Clostridium Difficile Infection. NCT02951481 | José María Aguado García, MD, PhD | — |
| Completed | Fecal Microbiota Transplantation (FMT) in Clostridium Difficile Infection (CDI) Not Responding to Antibiotics NCT03117582 | University of North Carolina, Chapel Hill | — |
| Completed | AssessmeNT of the Incidence of Clostridium Difficile Infections in Hospitalized Patients on Antibiotic TrEatme NCT02896244 | MJM Bonten | — |
| Completed | Observational Study of C. Diff in Post-Transplant Patients NCT02747017 | University of Minnesota | — |
| Unknown | Intestinal Lavage for the Treatment of Severe C. Difficile Infections NCT02466698 | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's | Phase 2 / Phase 3 |
| Completed | Fecal Microbiota Transplantation for Severe Clostridium Difficile Infection NCT03427229 | Catholic University of the Sacred Heart | Phase 2 |
| Enrolling By Invitation | Fecal Microbiome Transplant NCT02636517 | Judith Kelsen | Phase 1 |
| Terminated | To Evaluate the Impact of SBI on C. Difficile in Hospitalized UC Patients NCT02730325 | Northwestern University | N/A |
| Completed | A Study of SYN-004 for the Prevention of C.Diff in Patients With a LRTI NCT02563106 | Theriva Biologics, Inc. | Phase 2 |
| Completed | Chlorhexidine Bathing Effect on Clostridium Difficile Rates NCT02502682 | Jared Brooks | Phase 2 |
| Completed | Early FMT for C.Difficile NCT02465463 | Emory University | Phase 1 / Phase 2 |
| Completed | SER-109 Versus Placebo to Prevent Recurrent Clostridium Difficile Infection (RCDI) NCT02437487 | Seres Therapeutics, Inc. | Phase 2 |
| Completed | Fresh Versus Frozen Stool for Fecal Transplant in Children NCT02423967 | Mayo Clinic | Phase 1 |
| Terminated | Probiotics in the Reduction of Antibiotic Associated Diarrhea NCT02589964 | TriHealth Inc. | Phase 1 |
| Terminated | Safety of FMT: OpenBiome Outcomes and Longitudinal Follow-up (STOOL) for Recurrent Clostridium Difficile Infec NCT02403622 | Microbiome Health Research Institute | Phase 2 |
| Completed | Improved Adherence to C. Difficile Isolation Protocols Through Improved Education Methods NCT02375477 | Case Comprehensive Cancer Center | N/A |
| Terminated | Placebo Controlled Study of Fecal Microbiota Transplant (FMT) for a First or Second Episode of C. Difficile In NCT02343328 | Massachusetts General Hospital | Phase 1 |
| Completed | Dose-Confirmation, Immunogenicity and Safety Study of the Clostridium Difficile Vaccine Candidate VLA84 in Hea NCT02316470 | Valneva Austria GmbH | Phase 2 |
| Completed | A Phase IIIB/IV Study to Compare the Efficacy of Vancomycin Therapy to Extended Duration of Fidaxomicin Therap NCT02254967 | Astellas Pharma Europe Ltd. | Phase 4 |
| Completed | Effect of Multi-species Probiotic HOWARU® Restore, on Gut Microbiota of Elderly NCT02207140 | Gabriella C. van Zanten | EARLY_Phase 1 |
| Completed | Transplantation of Cultured Gut Microflora to Repeat Antibiotic-induced Diarrhea Due to Clostridium Difficile NCT02857582 | Per Hellström | Phase 2 |
| Terminated | Antibiotic Prophylaxis for Urinary Catheter Removal After Radical Prostatectomy NCT02247960 | University of Rochester | N/A |
| Completed | A Study to Compare Safety and Efficacy of OPT-80(Fidaxomicin) With Vancomycin in Subjects With Clostridium Dif NCT02179658 | Astellas Pharma Inc | Phase 3 |
| Completed | Mucosal Versus Fecal Microbiota in FMT NCT02133651 | Emory University | — |
| Terminated | Efficacy and Safety of Fecal Microbiota Transplantation for Severe Clostridium Difficile Associated Colitis NCT01959048 | Hadassah Medical Organization | N/A |
| Unknown | Seroprevalence of Anti-bodies Against Clostridium Difficile Toxins and Prevalence of Asymptomatic Carriage of NCT03889808 | Hospital Universitari de Bellvitge | — |
| Terminated | A Prospective Trial of Frozen-and-Thawed Fecal Microbiota Transplantation for Recurrent Clostridium Difficile NCT02394275 | McMaster University | Phase 2 |
| Completed | The Risk for Clostridium Difficile Colitis During Hospitalization in Asymptomatic Carriers NCT02063282 | Amos Yinnon | — |
| Terminated | Use Of Oral Fidaxomicin Vs. Oral Vancomycin For Clostridium Difficile Infection In Patients With Spinal Cord I NCT02355938 | Baylor College of Medicine | Phase 4 |
| Completed | A Study To Investigate A Clostridium Difficile Vaccine In Healthy Adults Aged 50 To 85 Years, Who Will Each Re NCT02052726 | Pfizer | Phase 1 |
| Unknown | Fecal Transplant for Pediatric Patients Who Have Recurrent C-diff Infection NCT02134392 | Jonathan Gisser | Phase 1 |
| Unknown | Fecal Microbiota Transplantation in Recurrent or Refractory Clostridium Difficile Colitis NCT01942447 | University Hospital Tuebingen | N/A |
| Unknown | Fecal Microbiota Therapy for Recurrent Clostridium Difficile Colitis NCT01973465 | OSF Healthcare System | N/A |
| Completed | Effects of Gastric Acid on Colonic Microbiome NCT01901276 | Daniel Freedberg, MD | Phase 4 |
| Completed | Fecal Microbiota Transplantation by Colonoscopy for Recurrent C. Difficile Infection NCT02148601 | Catholic University of the Sacred Heart | Phase 2 |
| Completed | Probiotics for Clostridium Difficile Infection in Older Adults NCT01680874 | University of Wisconsin, Madison | Phase 2 |
| Terminated | A Post-marketing, Blinded Study to Investigate How Effective Fidaxomicin is Compared to Vancomycin in the Sust NCT01775397 | Astellas Pharma Europe Ltd. | Phase 4 |
| Unknown | Fecal Transplant for Relapsing C. Difficile Infection NCT01703494 | Colleen Kelly | Phase 2 |
| Terminated | To Determine the Feasibility of a Fidaxomicin Study in Neonates and to Assess C. Difficile (Clostridium Diffic NCT01533844 | Astellas Pharma Europe B.V. | — |
| Completed | Host Immune Response to Clostridium Difficile Infection in Inflammatory Bowel Disease Patients NCT01813500 | Boston Medical Center | — |
| Terminated | Efficacy and Safety of Lactobacillus Acidophilus/Rhamnosus Combination for the Prevention of Antibiotic-associ NCT01048567 | Vancouver Island Health Authority | Phase 2 |
| Completed | Pharmacokinetics and Safety of Tigecycline in the Treatment of Clostridium Difficile Associated Diarrhea (CDAD NCT01401023 | Gary E. Stein, Pharm.D. | N/A |
| Terminated | Probiotic Saccharomyces Boulardii for the Prevention of Antibiotic-associated Diarrhoea NCT01143272 | Bernhard Nocht Institute for Tropical Medicine | Phase 3 |
| Completed | Lactobacillus Reuteri in the Prevention of Antibiotic Associated-diarrhea and Clostridium Difficile NCT02127814 | Case Western Reserve University | N/A |
| Completed | Probiotics in Preventing Antibiotic Associated Diarrhoea Including Clostridium Difficile Infection NCT01087892 | University of Sussex | N/A |
| Completed | Comparative Study of Three Different Testing Mechanisms for Clostridium Difficile NCT01066221 | Hamilton Health Sciences Corporation | — |
| Suspended | Efficacy of Loperamide for C. Difficile Colitis and Other Diarrheal Diseases Associated With Antibiotic Therap NCT00591357 | Michael E. DeBakey VA Medical Center | Phase 4 |
| Unknown | Probiotics: is it Really That Good? Cost-Effectiveness of Treating the in-Patient NCT00506181 | Hadassah Medical Organization | Phase 3 |
| Terminated | A Study to Assess the Safety, Tolerability, Effectiveness and Absorption of Exodif™ Tablets in Clostridium Dif NCT00466635 | Genzyme, a Sanofi Company | Phase 3 |
| Completed | Influence of a New Polycationic Disinfectant on Clostridium Difficile Incidence and Environmental Colonisation NCT00566306 | University of Helsinki | N/A |
| Unknown | Use of Recombinant Human Lactoferrin in Long-Term Care Patients With Feeding Tubes With Clostridium Difficile. NCT00377078 | Johns Hopkins University | N/A |
| Completed | Study of Nitazoxanide in the Treatment of Clostridium Difficile Colitis NCT00417872 | Romark Laboratories L.C. | Phase 2 |